Risk of acute mountain sickness · participants at risk of high altitude illness
Acetazolamide may leads to lower risk of acute mountain sickness compared with spironolactone (low certainty).
1 finding from 1 review
Risk of high altitude pulmonary oedema · participants at risk of high altitude illness
1 finding from 1 review
Risk of high altitude cerebral oedema · participants at risk of high altitude illness
1 finding from 1 review
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide probably leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (moderate certainty).
1 finding from 1 review
Risk of high altitude pulmonary oedema · participants at risk of high altitude illness
1 finding from 1 review
Incidence of high altitude cerebral oedema (HACE) ‐ not reported · participants at risk of high altitude illness
Acetazolamide showed no clear difference in incidence of high altitude cerebral oedema (HACE)‐ Follow‐ up: From… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: Paresthesias‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: side effects‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention may leads to lower ginkgo biloba versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS · participants at risk of high altitude illness
The intervention may leads to lower acetazolamide + ginkgo biloba versus ginkgo biloba: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + ginkgo biloba versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide versus medroxyprogesterone: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk… (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review